BiVACOR’s Artificial Heart Redefines Heart Replacement

Heart failure remains a leading cause of mortality worldwide, with a significant number of patients awaiting heart transplants due to the scarcity of donor organs. Addressing this critical need, BiVACOR has engineered a Total Artificial Heart (TAH) designed to replicate the functions of a natural heart, thereby offering hope to those with severe heart failure.

Innovative Design and Functionality

The BiVACOR TAH distinguishes itself through several key features:​

• Single Moving Part: The device incorporates a magnetically levitated rotor that serves as the sole moving component, reducing mechanical wear and enhancing durability.

• Dual Circulation Support: This rotor simultaneously pumps blood to both systemic and pulmonary circulations, effectively replacing the function of both ventricles.

• Compact and Durable: Constructed from titanium, the TAH is designed to fit within the chest cavity of most adults, offering a robust and biocompatible solution.

Clinical Milestones

BiVACOR's TAH has achieved significant clinical milestones:​

• First-in-Human Implantation: In July 2024, surgeons at Baylor St. Luke’s Medical Center in Houston successfully implanted the BiVACOR TAH into a patient with end-stage heart failure, marking a pivotal moment in artificial heart technology.

• Subsequent Implants: Following the initial success, additional implantations have been performed, including a notable case at Duke University Hospital where the TAH effectively supported a patient until a donor heart became available.

Future Outlook

As clinical trials progress, the BiVACOR TAH holds the potential to transform the landscape of heart failure treatment, providing a viable option for patients who may not have access to timely heart transplants. Ongoing research and development aim to refine the device further, enhancing its functionality and patient compatibility.